首页 / 院系成果 / 成果详情页

SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023 期刊论文

编号：

AE951B4F4DF43CD70CB81EB8F742FDC1
作者：

Chun, Helen M.^[1]Osawe, Sophia^[2];AdamsDabban, Samuel^[2];Favaloro, Jennifer^[1];Iriemenam, Nnaemeka C.^[3];Dirlikov, Emilio^[4]Martin, Diana^[5];Milligan, Kyle^[1,7];Abutu, Andrew^[3];Okunoye, Olumide^[3];Okoli, Mary^[6];Akanbi, Olusola^[6];Akinmulero, Oluwaseun^[2];Okonkwo, Rita^[2];Oyedele, Oyewole^[2];Greby, Stacie^[3];Abimiku, Alash''le^[2];Okoye, McPaul I. J.^[3];Shiraishi, Ray W.^[1];
语种：

英文
期刊：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES ISSN：1201-9712 2025 年 151 卷 ; FEB
疾病分类：

新型冠状病毒肺炎、艾滋病
关键词：

SARS-CoV-2 PLHIV COVID-19
摘要：

Objectives: Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria. Methods: We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status. Results: Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S +] and nucleocapsid [N +], (S + N +), ranged between 21.1% (95% confidence intervals [CI]: 11.431.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex. Conclusion: High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
推荐引用方式
GB/T 7714：

Chun Helen M.,Osawe Sophia,Adams-Dabban Samuel, et al. SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023 [J].INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES,2025,151.
APA：

Chun Helen M.,Osawe Sophia,Adams-Dabban Samuel,Favaloro Jennifer,&Shiraishi Ray W..(2025).SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023 .INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES,151.
MLA：

Chun Helen M., et al. "SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023" .INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 151(2025).
数据来源自科睿唯安Web of Science核心合集
入库时间：

2025/2/5 16:21:01
更新时间：

2025/2/5 16:21:01

浏览次数：134  下载次数：0

分享到：

浏览次数：134

下载次数：0

打印次数：0